SYRS - サイロス・ファ―マシュ―ティカルズ (Syros Pharmaceuticals Inc.)

SYRSのニュース

   The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings  2021/05/11 11:54:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV ) - Its Allergan subsidiary announced a deal to buy Soliton, Inc. (NASDAQ: SOLY ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Novo Nordisk A/S (NYSE: NVO ) Quest Diagnostics Incorporated (NYSE: DGX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 10) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 4D pharma plc (NASDAQ: LBPS ) Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) Acutus Medical, Inc. (NASDAQ: AFIB ) Adagene Inc. (NASDAQ: ADAG ) Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Aquestive Therapeutics, Inc. (NASDAQ: AQST ) Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) Athersys, Inc. (NASDAQ: ATHX ) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) (reacted to publication of positive results for a late-stage asset in lupus nephritis) Autolus Therapeutics plc (NASDAQ: AUTL ) AVROBIO, Inc.
   Cathie Wood Buys Yet Another Workhorse Dip, Also Adds DraftKings, Peloton, Square  2021/04/13 05:56:45 Benzinga
Cathie Wood-led Ark Investment Management on Monday bought in more shares of the electric vehicle company Workhorse Group Inc (NASDAQ: WKHS ) on a day the stock fell about 6% to $12.36, revealed a daily email showing the financial activity of the fund. The Ark Space Exploration & Innovation ETF (NYSE: ARKX ), the company’s newest fund, added 128,400 shares of Workhorse, representing about 0.25% of the total weight of the ETF. The ETF now owns 623,562 shares of the stock valued at $7.7 million and making up about 1.19% of the fund’s assets. The space fund is mainly focused on companies developing technology around spaceflight but companies such as Workhorse and agricultural equipment maker Deere & Co (NYSE: DE ) have found their way into the ETF. The investment firm’s daily trade disclosures sent every night to investors have in recent months caused certain stocks to see a spike in the after-hours session. Here’s a list of 37 more stocks that the hedge fund bought and sold on Monday. Trades For Ark Fintech Innovation ETF (NYSE: ARKF ): Opendoor Technologies Inc (NASDAQ: OPEN ): Bought 633,400 shares of the online real estate company, representing about 0.28% of the ETF.
   Syros Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones  2021/03/04 12:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter and full year ended December 31, 2020, and provided an update on recent accomplishments and upcoming events. “2021 promises to be a pivotal year for Syros,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “We moved our lead program into our first registration-enabling study and continu
   Earnings Scheduled For March 4, 2021  2021/03/04 09:07:02 Benzinga
Companies Reporting Before The Bell • Toro (NYSE: TTC ) is expected to report quarterly earnings at $0.75 per share on revenue of $851.38 million. • Autolus Therapeutics (NASDAQ: AUTL ) is projected to report quarterly loss at $0.77 per share on revenue of $340.00 thousand. • Azul (NYSE: AZUL ) is projected to report quarterly loss at $1.05 per share on revenue of $313.51 million. • Ballys (NYSE: BALY ) is estimated to report quarterly loss at $0.08 per share on revenue of $123.43 million. • Circor International (NYSE: CIR ) is estimated to report quarterly earnings at $0.63 per share on revenue of $207.57 million. • CRA International (NASDAQ: CRAI ) is projected to report quarterly earnings at $0.77 per share on revenue of $128.27 million. • Great Panther Mining Limited Ordinary Shares (Canada) (AMEX: GPL ) is likely to report earnings for its fourth quarter. • Global Ship Lease (NYSE: GSL ) is projected to report quarterly earnings at $0.43 per share on revenue of $69.18 million. • John Wiley & Sons, Inc.
   Syros to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 4, 2021  2021/02/25 13:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 4, 2021 to report its fourth quarter and full year 2020 financial results and provide a corporate update. To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 447246
   Cathie Wood Buys Yet Another Workhorse Dip, Also Adds DraftKings, Peloton, Square  2021/04/13 05:56:45 Benzinga
Cathie Wood-led Ark Investment Management on Monday bought in more shares of the electric vehicle company Workhorse Group Inc (NASDAQ: WKHS ) on a day the stock fell about 6% to $12.36, revealed a daily email showing the financial activity of the fund. The Ark Space Exploration & Innovation ETF (NYSE: ARKX ), the company’s newest fund, added 128,400 shares of Workhorse, representing about 0.25% of the total weight of the ETF. The ETF now owns 623,562 shares of the stock valued at $7.7 million and making up about 1.19% of the fund’s assets. The space fund is mainly focused on companies developing technology around spaceflight but companies such as Workhorse and agricultural equipment maker Deere & Co (NYSE: DE ) have found their way into the ETF. The investment firm’s daily trade disclosures sent every night to investors have in recent months caused certain stocks to see a spike in the after-hours session. Here’s a list of 37 more stocks that the hedge fund bought and sold on Monday. Trades For Ark Fintech Innovation ETF (NYSE: ARKF ): Opendoor Technologies Inc (NASDAQ: OPEN ): Bought 633,400 shares of the online real estate company, representing about 0.28% of the ETF.
   Syros Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones  2021/03/04 12:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter and full year ended December 31, 2020, and provided an update on recent accomplishments and upcoming events. “2021 promises to be a pivotal year for Syros,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “We moved our lead program into our first registration-enabling study and continu
   Earnings Scheduled For March 4, 2021  2021/03/04 09:07:02 Benzinga
Companies Reporting Before The Bell • Toro (NYSE: TTC ) is expected to report quarterly earnings at $0.75 per share on revenue of $851.38 million. • Autolus Therapeutics (NASDAQ: AUTL ) is projected to report quarterly loss at $0.77 per share on revenue of $340.00 thousand. • Azul (NYSE: AZUL ) is projected to report quarterly loss at $1.05 per share on revenue of $313.51 million. • Ballys (NYSE: BALY ) is estimated to report quarterly loss at $0.08 per share on revenue of $123.43 million. • Circor International (NYSE: CIR ) is estimated to report quarterly earnings at $0.63 per share on revenue of $207.57 million. • CRA International (NASDAQ: CRAI ) is projected to report quarterly earnings at $0.77 per share on revenue of $128.27 million. • Great Panther Mining Limited Ordinary Shares (Canada) (AMEX: GPL ) is likely to report earnings for its fourth quarter. • Global Ship Lease (NYSE: GSL ) is projected to report quarterly earnings at $0.43 per share on revenue of $69.18 million. • John Wiley & Sons, Inc.
   Syros to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 4, 2021  2021/02/25 13:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 4, 2021 to report its fourth quarter and full year 2020 financial results and provide a corporate update. To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 447246
   Syros to Participate in Upcoming Investor Conferences in March  2021/02/22 21:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that members of its management team will participate in panel discussions and present a corporate overview at upcoming investor conferences. Details are as follows: Cowen and Company 41st Annual Health Care Conference Date: Monday, March 1 Panel Title: Novel Oncology Targets Panel Time: 1:20 p.m. ET 33rd Annual Roth Conference Dat
   Syros Announces Pricing of $75.6 Million Public Offering of Common Stock  2021/01/20 03:41:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has priced an underwritten public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share, which would result in gross proceeds of approximately $75.6 million, before underwriting discounts and commissions. The proceeds of the offering are expected to be used to fund the development of
   Syros Announces Proposed Offering of Common Stock  2021/01/19 21:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it is offering to sell shares of its common stock in an underwritten public offering. The proceeds of the offering are expected to be used to fund the development of Syros’ ongoing clinical and preclinical programs, and for working capital and other general corporate purposes. All of the shares in the offering are to be sold
   Syros Announces Strategic Priorities and Expected Milestones  2021/01/11 12:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today outlined its strategic priorities and expected upcoming milestones. “Syros is rapidly accelerating toward becoming a commercial-stage company through three strategic priorities: advancing franchises in targeted hematology and selective CDK inhibition, as well as leveraging a robust gene control discovery engine to fuel our long-term growth,
   Syros to Present at 39th Annual J.P. Morgan Healthcare Conference  2021/01/07 13:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Conference. Details are as follows: 39th Annual J.P. Morgan Healthcare Conference: Date: Thursday, January 7 Time: 2:50 p.m. ET A live webcast of the presentation will be available on the Inve
   Syros Closes $90.5 Million Strategic Financing  2020/12/08 21:39:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has closed a previously announced private financing with a group of institutional accredited investors led by Bain Capital Life Sciences, with participation from new and existing investors, including Ally Bridge Group, Omega Funds, OrbiMed Advisors, EcoR1 Capital, and Samsara BioCapital. In this financing, Syros sold an ag

calendar